The team at Harmony Biosciences is excited to share that they have reached their enrollment goal for the Phase 3 RECONNECT trial and screening has officially closed.
A message to the Fragile X community from Dr. Kumar Budur, Chief Medical & Scientific Officer at Harmony Biosciences:
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Survey: Developing a Caregiver-Reported Survey in Neurodevelopmental Disorders: The Neurodevelopmental Disorder-Health Index (NDD-HI)
The Center of Health and Technology’s (CheT) Outcomes Division is conducting is conducting a survey to learn about the most prevalent and impactful symptoms of FXS that the individual experiences, as reported by the caregiver.
Why is the RECONNECT trial with ZYN002 Being Conducted in Fragile X Syndrome?
Zynerba Pharmaceuticals shares why the RECONNECT trial with ZYN002 is being conducted in Fragile X syndrome